Personalized Treatment of Colorectal Cancer After 2 Lines of Therapy

Register Now

This interactive, expert-led symposium features a quiz game format and reinforces how best to personalize and optimize care for patients with metastatic colorectal cancer and multiple treatment failures.

Not an official event of the 2017 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation.


  • Welcome and Program OverviewJohn L. Marshall, MD
  • Personalized Treatment Selection for Metastatic CRC After Multiple Lines of Therapy Have Failed – Axel Grothey, MD
  • Patient Education and Management of Adverse Events to Improve Outcomes With Later Lines of Therapy for Metastatic CRC – Tanios Bekaii-Saab, MD, FACP
  • Future Directions and New Perspectives on Treating Metastatic CRC – John L. Marshall, MD
  • Closing Remarks – John L. Marshall, MD



Date / Time
Event Details


Program Chair
John Marshall, MD

Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Tanios Bekaii-Saab, MD, FACP

Mayo Clinic College of Medicine and Science
Co-Leader, GI Cancer Program
Mayo Clinic Cancer Center
Senior Associate Consultant
Mayo Clinic Arizona
Phoenix, Arizona

Axel Grothey, MD

Professor, Oncology
Mayo Clinic
Rochester, Minnesota


Goal Statement
The goal of this activity is to improve participants’ competence in and performance at providing personalized care for patients with metastatic colorectal cancer who have already experienced treatment failure on fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti-VEGF therapy; and if RAS wild type, an anti-EGFR therapy.

Target Audience
This program is intended for oncologists and other healthcare providers who care for patients with metastatic colorectal cancer.

Learning Objectives

  • Plan optimal, personalized treatment strategies for patients with metastatic CRC who have experienced failure of at least 2 lines of therapy
  • Develop preventive and emergent strategies to limit or resolve potential adverse events associated with newer agents used in the treatment of metastatic CRC
  • Communicate with patients to help them make informed decisions and actively participate in their care
  • Identify patients with metastatic CRC who may benefit from enrollment on clinical trials evaluating immune checkpoint inhibitors and other targeted agents


Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.